Pneumococcal conjugate vaccine use for the prevention of pneumococcal disease in adults <50 years of age

Pneumococcal conjugate vaccine use for the prevention of pneumococcal disease in adults <50 years of age

Introduction; Adults, particularly those with underlying chronic conditions, eg, cardiovascular, liver, and pulmonary diseases and diabetes mellitus, have a persistent pneumococcal disease burden. Thirteen-valent pneumococcal conjugate vaccine (PCV13) is recommended in the United States for all adul...

Full description

Bibliographic Details
Main Authors: Raul E. Isturiz, Cassandra Hall-Murray, John M. McLaughlin, Vincenza Snow, Beate Schmoele-Thoma, Chris Webber, Allison Thompson, Daniel A Scott
Format: Article
Language:English
Published: Taylor & Francis Group 2018-01-01
Series:Expert Review of Vaccines
Subjects:
adults
burden of disease
cap
community-acquired pneumonia
ipd
prevnar 13
streptococcus pneumoniae
vaccine recommendation
Online Access:http://dx.doi.org/10.1080/14760584.2018.1411196

Internet

http://dx.doi.org/10.1080/14760584.2018.1411196

Similar Items